Monday, December 2 | 8:20 a.m.-8:30 a.m. | M1-SSNMMI02-3 | Room S405
Certain prostate cancer features on prostate specific membrane antigen (PSMA)-PET may be useful in selecting candidates who are more likely to respond to lutetium-177 (Lu-177) PSMA-617, according to a study in this session. PSMA expression in prostate cancer cells varies and there is a scarcity of research on factors that lead to higher PSMA expression, the group noted.
To that end, presenter Jackson Sullivan, a medical student at Wake Forest University, and colleagues analyze factors impacting minimum standardized uptake value (SUVmin), maximum SUV (SUVmax), and mean SUV (SUVmean) in a group of 34 patients who underwent PSMA-PET/CT during treatment.
According to the findings, patients with Gleason scores of 6, 7, or 8 had significantly higher SUVmin compared with those with Gleason scores of 9 or 10 (SUVmin median 4.6 vs. 4, p = 0.0275). Patients previously treated with enzalutamide also had significantly higher SUVmin values than those who were not (SUVmin median 5 vs. 4.3, p = 0.0484). Patients with visceral lesions compared to those with no visceral lesions had significantly higher SUVmin (SUVmin median 5 vs. 4.3, p = 0.0429). And patients who were previously treated with olaparib had significantly higher SUVmax than those who were not (SUVmax median 151.5 vs. 34, p = 0.0191).
Moreover, bone tumor volume had a significant correlation with SUVmax (Spearman correlation: 0.6314, p = 0.0001) and SUVmean (Spearman correlation: 0.3448, p = 0.0458) and total tumor volume had a significant correlation with SUVmax (Spearman correlation: 0.6867, p = 0.0001) and SUVmean (Spearman correlation: 0.4915, p = 0.0032), according to the study.
“Some prostate cancer treatments prior to PSMA PET/CT can enhance the PSMA expression and SUV," the group concluded. "This information can be utilized for careful selection of the patients undergoing Lu-177 PSMA-617 therapy."
This nuclear medicine scientific session is dedicated to prostate cancer imaging. Check it out for all the details.
